#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-10	Functional	_
1-2	11-23	neuroimaging	_
1-3	24-31	effects	_
1-4	32-34	of	_
1-5	35-43	recently	_
1-6	44-54	discovered	_
1-7	55-62	genetic	_
1-8	63-67	risk	_
1-9	68-72	loci	_
1-10	73-76	for	_
1-11	77-90	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-12	91-94	and	_
1-13	95-104	polygenic	_
1-14	105-109	risk	_
1-15	110-117	profile	_
1-16	118-120	in	_
1-17	121-125	five	_
1-18	126-130	RDoC	_
1-19	131-141	subdomains	_
1-20	142-150	Recently	_
1-21	151-152	,	_
1-22	153-156	125	_
1-23	157-161	loci	_
1-24	162-166	with	_
1-25	167-178	genome-wide	_
1-26	179-186	support	_
1-27	187-190	for	_
1-28	191-202	association	_
1-29	203-207	with	_
1-30	208-221	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-31	222-226	were	_
1-32	227-237	identified	_
1-33	238-239	.	_

2-1	240-242	We	_
2-2	243-255	investigated	_
2-3	256-259	the	_
2-4	260-266	impact	_
2-5	267-269	of	_
2-6	270-275	these	_
2-7	276-284	variants	_
2-8	285-288	and	_
2-9	289-294	their	_
2-10	295-306	accumulated	_
2-11	307-314	genetic	_
2-12	315-319	risk	_
2-13	320-322	on	_
2-14	323-328	brain	_
2-15	329-339	activation	_
2-16	340-342	in	_
2-17	343-347	five	_
2-18	348-362	neurocognitive	_
2-19	363-370	domains	_
2-20	371-373	of	_
2-21	374-377	the	_
2-22	378-386	Research	_
2-23	387-393	Domain	_
2-24	394-402	Criteria	_
2-25	403-404	(	_
2-26	405-412	working	_
2-27	413-419	memory	_
2-28	420-421	,	_
2-29	422-428	reward	_
2-30	429-439	processing	_
2-31	440-441	,	_
2-32	442-450	episodic	_
2-33	451-457	memory	_
2-34	458-459	,	_
2-35	460-466	social	_
2-36	467-476	cognition	_
2-37	477-480	and	_
2-38	481-488	emotion	_
2-39	489-499	processing	_
2-40	500-501	)	_
2-41	502-503	.	_

3-1	504-506	In	_
3-2	507-510	578	_
3-3	511-518	healthy	_
3-4	519-527	subjects	_
3-5	528-530	we	_
3-6	531-537	tested	_
3-7	538-541	for	_
3-8	542-553	association	_
3-9	554-555	(	_
3-10	556-557	i	_
3-11	558-559	)	_
3-12	560-562	of	_
3-13	563-564	a	_
3-14	565-574	polygenic	_
3-15	575-579	risk	_
3-16	580-587	profile	_
3-17	588-593	score	_
3-18	594-595	(	_
3-19	596-599	RPS	_
3-20	600-601	)	_
3-21	602-611	including	_
3-22	612-615	all	_
3-23	616-633	single-nucleotide	_
3-24	634-647	polymorphisms	_
3-25	648-649	(	_
3-26	650-654	SNPs	_
3-27	655-656	)	_
3-28	657-665	reaching	_
3-29	666-677	genome-wide	_
3-30	678-690	significance	_
3-31	691-693	in	_
3-32	694-697	the	_
3-33	698-704	recent	_
3-34	705-716	genome-wide	_
3-35	717-728	association	_
3-36	729-736	studies	_
3-37	737-738	(	_
3-38	739-743	GWAS	_
3-39	744-745	)	_
3-40	746-759	meta-analysis	_
3-41	760-763	and	_
3-42	764-765	(	_
3-43	766-768	ii	_
3-44	769-770	)	_
3-45	771-773	of	_
3-46	774-777	all	_
3-47	778-789	independent	_
3-48	790-801	genome-wide	_
3-49	802-813	significant	_
3-50	814-818	loci	_
3-51	819-829	separately	_
3-52	830-834	that	_
3-53	835-841	showed	_
3-54	842-852	sufficient	_
3-55	853-865	distribution	_
3-56	866-868	of	_
3-57	869-872	all	_
3-58	873-880	allelic	_
3-59	881-887	groups	_
3-60	888-890	in	_
3-61	891-894	our	_
3-62	895-901	sample	_
3-63	902-903	(	_
3-64	904-907	105	_
3-65	908-912	SNPs	_
3-66	913-914	)	_
3-67	915-916	.	_

4-1	917-920	The	_
4-2	921-924	RPS	_
4-3	925-928	was	_
4-4	929-938	nominally	_
4-5	939-949	associated	_
4-6	950-954	with	_
4-7	955-965	perigenual	_
4-8	966-974	anterior	_
4-9	975-984	cingulate	_
4-10	985-988	and	_
4-11	989-998	posterior	_
4-12	999-1018	cingulate/precuneus	_
4-13	1019-1029	activation	_
4-14	1030-1036	during	_
4-15	1037-1045	episodic	_
4-16	1046-1052	memory	_
4-17	1053-1054	(	_
4-18	1055-1059	PFWE	_
4-19	1060-1061	(	_
4-20	1062-1065	ROI	_
4-21	1066-1067	)	_
4-22	1068-1074	=0.047	_
4-23	1075-1076	)	_
4-24	1077-1080	and	_
4-25	1081-1087	social	_
4-26	1088-1097	cognition	_
4-27	1098-1099	(	_
4-28	1100-1104	PFWE	_
4-29	1105-1106	(	_
4-30	1107-1110	ROI	_
4-31	1111-1112	)	_
4-32	1113-1119	=0.025	_
4-33	1120-1121	)	_
4-34	1122-1123	,	_
4-35	1124-1136	respectively	_
4-36	1137-1138	.	_

5-1	1139-1145	Single	_
5-2	1146-1149	SNP	_
5-3	1150-1158	analyses	_
5-4	1159-1167	revealed	_
5-5	1168-1172	that	_
5-6	1173-1182	rs9607782	_
5-7	1183-1184	,	_
5-8	1185-1192	located	_
5-9	1193-1197	near	_
5-10	1198-1203	EP300	_
5-11	1204-1205	,	_
5-12	1206-1209	was	_
5-13	1210-1223	significantly	_
5-14	1224-1234	associated	_
5-15	1235-1239	with	_
5-16	1240-1248	amygdala	_
5-17	1249-1260	recruitment	_
5-18	1261-1267	during	_
5-19	1268-1275	emotion	_
5-20	1276-1286	processing	_
5-21	1287-1288	(	_
5-22	1289-1293	PFWE	_
5-23	1294-1295	(	_
5-24	1296-1299	ROI	_
5-25	1300-1301	)	_
5-26	1302-1307	=1.63	_
5-27	1308-1309	×	_
5-28	1310-1314	10−4	_
5-29	1315-1316	,	_
5-30	1317-1327	surpassing	_
5-31	1328-1338	Bonferroni	_
5-32	1339-1349	correction	_
5-33	1350-1353	for	_
5-34	1354-1357	the	_
5-35	1358-1364	number	_
5-36	1365-1367	of	_
5-37	1368-1372	SNPs	_
5-38	1373-1374	)	_
5-39	1375-1376	.	_

6-1	1377-1388	Importantly	_
6-2	1389-1390	,	_
6-3	1391-1395	this	_
6-4	1396-1407	association	_
6-5	1408-1411	was	_
6-6	1412-1422	replicable	_
6-7	1423-1425	in	_
6-8	1426-1428	an	_
6-9	1429-1440	independent	_
6-10	1441-1447	sample	_
6-11	1448-1449	(	_
6-12	1450-1455	N=150	_
6-13	1456-1457	;	_
6-14	1458-1462	PFWE	_
6-15	1463-1464	(	_
6-16	1465-1468	ROI	_
6-17	1469-1470	)	_
6-18	1471-1472	<	_
6-19	1473-1478	0.025	_
6-20	1479-1480	)	_
6-21	1481-1482	.	_

7-1	1483-1488	Other	_
7-2	1489-1492	SNP	_
7-3	1493-1500	effects	_
7-4	1501-1511	previously	_
7-5	1512-1522	associated	_
7-6	1523-1527	with	_
7-7	1528-1535	imaging	_
7-8	1536-1546	phenotypes	_
7-9	1547-1551	were	_
7-10	1552-1561	nominally	_
7-11	1562-1573	significant	_
7-12	1574-1575	,	_
7-13	1576-1579	but	_
7-14	1580-1583	did	_
7-15	1584-1587	not	_
7-16	1588-1597	withstand	_
7-17	1598-1608	correction	_
7-18	1609-1612	for	_
7-19	1613-1616	the	_
7-20	1617-1623	number	_
7-21	1624-1626	of	_
7-22	1627-1631	SNPs	_
7-23	1632-1638	tested	_
7-24	1639-1640	.	_

8-1	1641-1643	To	_
8-2	1644-1650	assess	_
8-3	1651-1658	whether	_
8-4	1659-1664	there	_
8-5	1665-1668	was	_
8-6	1669-1673	true	_
8-7	1674-1680	signal	_
8-8	1681-1687	within	_
8-9	1688-1691	our	_
8-10	1692-1696	data	_
8-11	1697-1698	,	_
8-12	1699-1701	we	_
8-13	1702-1710	repeated	_
8-14	1711-1717	single	_
8-15	1718-1721	SNP	_
8-16	1722-1730	analyses	_
8-17	1731-1735	with	_
8-18	1736-1739	105	_
8-19	1740-1748	randomly	_
8-20	1749-1755	chosen	_
8-21	1756-1784	non-schizophrenia-associated	_
8-22	1785-1793	variants	_
8-23	1794-1795	,	_
8-24	1796-1805	observing	_
8-25	1806-1811	fewer	_
8-26	1812-1823	significant	_
8-27	1824-1831	results	_
8-28	1832-1835	and	_
8-29	1836-1841	lower	_
8-30	1842-1853	association	_
8-31	1854-1867	probabilities	_
8-32	1868-1869	.	_

9-1	1870-1878	Applying	_
9-2	1879-1888	stringent	_
9-3	1889-1903	methodological	_
9-4	1904-1914	procedures	_
9-5	1915-1916	,	_
9-6	1917-1919	we	_
9-7	1920-1925	found	_
9-8	1926-1937	preliminary	_
9-9	1938-1946	evidence	_
9-10	1947-1950	for	_
9-11	1951-1954	the	_
9-12	1955-1961	notion	_
9-13	1962-1966	that	_
9-14	1967-1974	genetic	_
9-15	1975-1979	risk	_
9-16	1980-1983	for	_
9-17	1984-1997	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-18	1998-2007	conferred	_
9-19	2008-2010	by	_
9-20	2011-2020	rs9607782	_
9-21	2021-2024	may	_
9-22	2025-2027	be	_
9-23	2028-2036	mediated	_
9-24	2037-2039	by	_
9-25	2040-2048	amygdala	_
9-26	2049-2057	function	_
9-27	2058-2059	.	_

10-1	2060-2062	We	_
10-2	2063-2073	critically	_
10-3	2074-2082	evaluate	_
10-4	2083-2086	the	_
10-5	2087-2096	potential	_
10-6	2097-2104	caveats	_
10-7	2105-2107	of	_
10-8	2108-2111	the	_
10-9	2112-2126	methodological	_
10-10	2127-2137	approaches	_
10-11	2138-2146	employed	_
10-12	2147-2150	and	_
10-13	2151-2156	offer	_
10-14	2157-2168	suggestions	_
10-15	2169-2172	for	_
10-16	2173-2179	future	_
10-17	2180-2187	studies	_
10-18	2188-2189	.	_

11-1	2190-2199	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-2	2200-2203	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-3	2204-2211	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-4	2212-2220	Subjects	_
11-5	2221-2222	A	_
11-6	2223-2228	total	_
11-7	2229-2231	of	_
11-8	2232-2235	578	_
11-9	2236-2242	German	_
11-10	2243-2253	volunteers	_
11-11	2254-2257	who	_
11-12	2258-2263	never	_
11-13	2264-2272	suffered	_
11-14	2273-2277	from	_
11-15	2278-2289	psychiatric	_
11-16	2290-2298	disorder	_
11-17	2299-2300	(	_
11-18	2301-2310	evidenced	_
11-19	2311-2313	by	_
11-20	2314-2320	SCID-I	_
11-21	2321-2322	)	_
11-22	2323-2327	were	_
11-23	2328-2337	recruited	_
11-24	2338-2340	at	_
11-25	2341-2349	Mannheim	_
11-26	2350-2351	,	_
11-27	2352-2358	Berlin	_
11-28	2359-2362	and	_
11-29	2363-2367	Bonn	_
11-30	2368-2370	as	_
11-31	2371-2375	part	_
11-32	2376-2378	of	_
11-33	2379-2381	an	_
11-34	2382-2389	ongoing	_
11-35	2390-2395	study	_
11-36	2396-2398	on	_
11-37	2399-2411	neurogenetic	_
11-38	2412-2422	mechanisms	_
11-39	2423-2425	of	_
11-40	2426-2434	unipolar	_
11-41	2435-2445	depression	_
11-42	2446-2447	,	_
11-43	2448-2455	bipolar	_
11-44	2456-2464	disorder	_
11-45	2465-2468	and	_
11-46	2469-2482	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-47	2483-2484	(	_
11-48	2485-2489	http	_
11-49	2490-2491	:	_
11-50	2492-2509	//www.ngfn.de/en/	_
11-51	2510-2528	schizophrenie.html	_
11-52	2529-2530	;	_
11-53	2531-2535	http	_
11-54	2536-2537	:	_
11-55	2538-2580	//www.sys-med.de/en/consortia/integrament/	_
11-56	2581-2582	)	_
11-57	2583-2584	.	_

12-1	2585-2590	N=333	_
12-2	2591-2603	participants	_
12-3	2604-2607	had	_
12-4	2608-2610	no	_
12-5	2611-2619	lifetime	_
12-6	2620-2626	family	_
12-7	2627-2634	history	_
12-8	2635-2637	of	_
12-9	2638-2651	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-10	2652-2654	or	_
12-11	2655-2657	an	_
12-12	2658-2667	affective	_
12-13	2668-2676	disorder	_
12-14	2677-2678	,	_
12-15	2679-2682	and	_
12-16	2683-2688	n=245	_
12-17	2689-2697	subjects	_
12-18	2698-2701	had	_
12-19	2702-2704	at	_
12-20	2705-2710	least	_
12-21	2711-2714	one	_
12-22	2715-2727	first-degree	_
12-23	2728-2736	relative	_
12-24	2737-2745	affected	_
12-25	2746-2748	by	_
12-26	2749-2762	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-27	2763-2764	(	_
12-28	2765-2769	n=72	_
12-29	2770-2771	)	_
12-30	2772-2773	,	_
12-31	2774-2781	bipolar	_
12-32	2782-2790	disorder	_
12-33	2791-2792	(	_
12-34	2793-2797	n=71	_
12-35	2798-2799	)	_
12-36	2800-2802	or	_
12-37	2803-2813	depression	_
12-38	2814-2815	(	_
12-39	2816-2821	n=102	_
12-40	2822-2823	)	_
12-41	2824-2825	.	_

13-1	2826-2834	Affected	_
13-2	2835-2840	index	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-3	2841-2849	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-4	2850-2853	did	_
13-5	2854-2857	not	_
13-6	2858-2864	suffer	_
13-7	2865-2869	from	_
13-8	2870-2873	any	_
13-9	2874-2879	other	_
13-10	2880-2889	psychotic	_
13-11	2890-2892	or	_
13-12	2893-2902	affective	_
13-13	2903-2911	disorder	_
13-14	2912-2913	,	_
13-15	2914-2917	and	_
13-16	2918-2921	the	_
13-17	2922-2934	investigated	_
13-18	2935-2944	relatives	_
13-19	2945-2948	had	_
13-20	2949-2951	no	_
13-21	2952-2958	family	_
13-22	2959-2966	history	_
13-23	2967-2969	of	_
13-24	2970-2978	multiple	_
13-25	2979-2988	different	_
13-26	2989-3000	psychiatric	_
13-27	3001-3010	diagnoses	_
13-28	3011-3012	(	_
13-29	3013-3016	for	_
13-30	3017-3024	example	_
13-31	3025-3026	,	_
13-32	3027-3032	cases	_
13-33	3033-3035	of	_
13-34	3036-3040	both	_
13-35	3041-3042	,	_
13-36	3043-3052	affective	_
13-37	3053-3056	and	_
13-38	3057-3066	psychotic	_
13-39	3067-3076	disorders	_
13-40	3077-3078	)	_
13-41	3079-3080	.	_

14-1	3081-3084	All	_
14-2	3085-3093	subjects	_
14-3	3094-3097	had	_
14-4	3098-3110	grandparents	_
14-5	3111-3113	of	_
14-6	3114-3122	European	_
14-7	3123-3129	origin	_
14-8	3130-3131	.	_

15-1	3132-3141	Following	_
15-2	3142-3153	application	_
15-3	3154-3156	of	_
15-4	3157-3166	exclusion	_
15-5	3167-3175	criteria	_
15-6	3176-3185	n=472–509	_
15-7	3186-3194	subjects	_
15-8	3195-3199	were	_
15-9	3200-3208	included	_
15-10	3209-3211	in	_
15-11	3212-3215	the	_
15-12	3216-3224	analyses	_
15-13	3225-3227	of	_
15-14	3228-3231	the	_
15-15	3232-3242	respective	_
15-16	3243-3248	tasks	_
15-17	3249-3250	(	_
15-18	3251-3254	see	_
15-19	3255-3268	Supplementary	_
15-20	3269-3277	Material	_
15-21	3278-3281	for	_
15-22	3282-3289	details	_
15-23	3290-3291	)	_
15-24	3292-3293	.	_

16-1	3294-3299	N=150	_
16-2	3300-3308	controls	_
16-3	3309-3318	recruited	_
16-4	3319-3321	as	_
16-5	3322-3326	part	_
16-6	3327-3329	of	_
16-7	3330-3331	a	_
16-8	3332-3337	study	_
16-9	3338-3340	on	_
16-10	3341-3344	the	_
16-11	3345-3357	neurogenetic	_
16-12	3358-3368	mechanisms	_
16-13	3369-3371	of	_
16-14	3372-3379	alcohol	_
16-15	3380-3390	dependence	_
16-16	3391-3393	in	_
16-17	3394-3400	Berlin	_
16-18	3401-3404	and	_
16-19	3405-3409	Bonn	_
16-20	3410-3411	(	_
16-21	3412-3416	http	_
16-22	3417-3418	:	_
16-23	3419-3461	//www.ngfn.de/en/alkoholabh__ngigkeit.html	_
16-24	3462-3463	)	_
16-25	3464-3470	served	_
16-26	3471-3473	as	_
16-27	3474-3485	replication	_
16-28	3486-3492	sample	_
16-29	3493-3494	.	_

17-1	3495-3498	All	_
17-2	3499-3511	participants	_
17-3	3512-3517	never	_
17-4	3518-3526	suffered	_
17-5	3527-3531	from	_
17-6	3532-3543	psychiatric	_
17-7	3544-3552	disorder	_
17-8	3553-3562	according	_
17-9	3563-3565	to	_
17-10	3566-3569	the	_
17-11	3570-3580	Structured	_
17-12	3581-3589	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalDocument
17-13	3590-3599	Interview	_
17-14	3600-3602	of	_
17-15	3603-3606	the	_
17-16	3607-3617	Diagnostic	_
17-17	3618-3621	and	_
17-18	3622-3633	Statistical	_
17-19	3634-3640	Manual	http://maven.renci.org/NeuroBridge/neurobridge#MercurySphygmomanometer
17-20	3641-3643	of	_
17-21	3644-3650	Mental	_
17-22	3651-3660	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalDisease
17-23	3661-3662	(	_
17-24	3663-3669	DSM-IV	_
17-25	3670-3671	)	_
17-26	3672-3678	Axis-I	_
17-27	3679-3688	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalDisease
17-28	3689-3690	(	_
17-29	3691-3697	SCID-I	_
17-30	3698-3699	)	_
17-31	3700-3701	.	_

18-1	3702-3713	Demographic	_
18-2	3714-3729	characteristics	_
18-3	3730-3732	of	_
18-4	3733-3736	the	_
18-5	3737-3747	respective	_
18-6	3748-3758	subsamples	_
18-7	3759-3762	are	_
18-8	3763-3768	given	_
18-9	3769-3771	in	_
18-10	3772-3785	Supplementary	_
18-11	3786-3792	Tables	_
18-12	3793-3795	S1	_
18-13	3796-3799	and	_
18-14	3800-3802	S2	_
18-15	3803-3804	.	_

19-1	3805-3808	The	_
19-2	3809-3814	study	_
19-3	3815-3818	was	_
19-4	3819-3827	approved	_
19-5	3828-3830	by	_
19-6	3831-3836	local	_
19-7	3837-3843	ethics	_
19-8	3844-3854	committees	_
19-9	3855-3857	of	_
19-10	3858-3861	the	_
19-11	3862-3874	universities	_
19-12	3875-3877	of	_
19-13	3878-3888	Heidelberg	_
19-14	3889-3890	,	_
19-15	3891-3897	Berlin	_
19-16	3898-3901	and	_
19-17	3902-3906	Bonn	_
19-18	3907-3908	.	_

20-1	3909-3912	All	_
20-2	3913-3925	participants	_
20-3	3926-3930	gave	_
20-4	3931-3938	written	_
20-5	3939-3947	informed	_
20-6	3948-3955	consent	_
20-7	3956-3958	to	_
20-8	3959-3962	the	_
20-9	3963-3968	study	_
20-10	3969-3978	according	_
20-11	3979-3981	to	_
20-12	3982-3985	the	_
20-13	3986-3997	Declaration	_
20-14	3998-4000	of	_
20-15	4001-4009	Helsinki	_
20-16	4010-4011	.	_

21-1	4012-4015	DNA	_
21-2	4016-4026	extraction	_
21-3	4027-4030	and	_
21-4	4031-4041	genotyping	_
21-5	4042-4068	Ethylenediaminetetraacetic	_
21-6	4069-4073	acid	_
21-7	4074-4088	anticoagulated	_
21-8	4089-4095	venous	_
21-9	4096-4101	blood	_
21-10	4102-4109	samples	_
21-11	4110-4114	were	_
21-12	4115-4124	collected	_
21-13	4125-4129	from	_
21-14	4130-4133	all	_
21-15	4134-4145	individuals	_
21-16	4146-4147	.	_

22-1	4148-4158	Lymphocyte	_
22-2	4159-4162	DNA	_
22-3	4163-4166	was	_
22-4	4167-4175	isolated	_
22-5	4176-4181	using	_
22-6	4182-4185	the	_
22-7	4186-4194	Chemagic	_
22-8	4195-4203	Magnetic	_
22-9	4204-4214	Separation	_
22-10	4215-4221	Module	_
22-11	4222-4223	I	_
22-12	4224-4225	(	_
22-13	4226-4234	Chemagen	_
22-14	4235-4236	,	_
22-15	4237-4247	Baesweiler	_
22-16	4248-4249	,	_
22-17	4250-4257	Germany	_
22-18	4258-4259	)	_
22-19	4260-4269	according	_
22-20	4270-4272	to	_
22-21	4273-4276	the	_
22-22	4277-4289	manufacturer	_
22-23	4290-4291	’	_
22-24	4292-4293	s	_
22-25	4294-4309	recommendations	_
22-26	4310-4311	.	_

23-1	4312-4313	A	_
23-2	4314-4325	genome-wide	_
23-3	4326-4330	data	_
23-4	4331-4334	set	_
23-5	4335-4338	was	_
23-6	4339-4348	generated	_
23-7	4349-4351	at	_
23-8	4352-4355	the	_
23-9	4356-4366	Department	_
23-10	4367-4369	of	_
23-11	4370-4378	Genomics	_
23-12	4379-4380	,	_
23-13	4381-4385	Life	_
23-14	4386-4387	&	_
23-15	4388-4393	Brain	_
23-16	4394-4400	Center	_
23-17	4401-4402	,	_
23-18	4403-4413	University	_
23-19	4414-4416	of	_
23-20	4417-4421	Bonn	_
23-21	4422-4427	using	_
23-22	4428-4436	Illumina	_
23-23	4437-4438	’	_
23-24	4439-4440	s	_
23-25	4441-4453	Human610Quad	_
23-26	4454-4455	,	_
23-27	4456-4470	Human660W-Quad	_
23-28	4471-4474	and	_
23-29	4475-4483	Infinium	_
23-30	4484-4497	PsychArray-24	_
23-31	4498-4507	BeadChips	_
23-32	4508-4509	(	_
23-33	4510-4518	Illumina	_
23-34	4519-4520	,	_
23-35	4521-4524	San	_
23-36	4525-4530	Diego	_
23-37	4531-4532	,	_
23-38	4533-4535	CA	_
23-39	4536-4537	,	_
23-40	4538-4541	USA	_
23-41	4542-4543	)	_
23-42	4544-4545	.	_

24-1	4546-4553	Quality	_
24-2	4554-4561	control	_
24-3	4562-4565	and	_
24-4	4566-4576	imputation	_
24-5	4577-4581	were	_
24-6	4582-4591	performed	_
24-7	4592-4596	with	_
24-8	4597-4605	standard	_
24-9	4606-4616	parameters	_
24-10	4617-4621	used	_
24-11	4622-4624	by	_
24-12	4625-4628	the	_
24-13	4629-4640	Psychiatric	_
24-14	4641-4649	Genetics	_
24-15	4650-4660	Consortium	_
24-16	4661-4662	(	_
24-17	4663-4666	PGC	_
24-18	4667-4668	)	_
24-19	4669-4680	Statistical	_
24-20	4681-4689	Analyses	_
24-21	4690-4695	Group	_
24-22	4696-4699	and	_
24-23	4700-4703	RPS	_
24-24	4704-4708	were	_
24-25	4709-4719	calculated	_
24-26	4720-4725	using	_
24-27	4726-4733	methods	_
24-28	4734-4743	described	_
24-29	4744-4746	by	_
24-30	4747-4754	Purcell	_
24-31	4755-4757	et	_
24-32	4758-4760	al	_
24-33	4761-4762	.	_

25-1	4763-4764	(	_
25-2	4765-4768	see	_
25-3	4769-4782	Supplementary	_
25-4	4783-4791	Material	_
25-5	4792-4795	for	_
25-6	4796-4803	details	_
25-7	4804-4805	)	_
25-8	4806-4807	.	_

26-1	4808-4818	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
26-2	4819-4826	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
26-3	4827-4832	tasks	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
26-4	4833-4839	During	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
26-5	4840-4850	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
26-6	4851-4859	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
26-7	4860-4869	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
26-8	4870-4877	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
26-9	4878-4879	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
26-10	4880-4884	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
26-11	4885-4886	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
26-12	4887-4895	subjects	_
26-13	4896-4905	completed	_
26-14	4906-4908	an	_
26-15	4909-4920	associative	http://maven.renci.org/NeuroBridge/neurobridge#Episodic
26-16	4921-4929	episodic	http://maven.renci.org/NeuroBridge/neurobridge#Episodic
26-17	4930-4936	memory	http://maven.renci.org/NeuroBridge/neurobridge#Episodic
26-18	4937-4938	(	http://maven.renci.org/NeuroBridge/neurobridge#Episodic
26-19	4939-4941	EM	http://maven.renci.org/NeuroBridge/neurobridge#Episodic
26-20	4942-4943	)	http://maven.renci.org/NeuroBridge/neurobridge#Episodic
26-21	4944-4948	task	http://maven.renci.org/NeuroBridge/neurobridge#Episodic
26-22	4949-4958	requiring	_
26-23	4959-4967	encoding	_
26-24	4968-4969	,	_
26-25	4970-4976	recall	_
26-26	4977-4980	and	_
26-27	4981-4992	recognition	_
26-28	4993-4995	of	_
26-29	4996-5011	face-profession	_
26-30	5012-5017	pairs	_
26-31	5018-5019	.	_

27-1	5020-5023	The	_
27-2	5024-5026	WM	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
27-3	5027-5033	n-back	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
27-4	5034-5038	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
27-5	5039-5047	required	_
27-6	5048-5058	continuous	_
27-7	5059-5067	updating	_
27-8	5068-5071	and	_
27-9	5072-5081	retrieval	_
27-10	5082-5084	of	_
27-11	5085-5093	elements	_
27-12	5094-5098	held	_
27-13	5099-5101	in	_
27-14	5102-5112	short-time	_
27-15	5113-5119	memory	_
27-16	5120-5121	.	_

28-1	5122-5125	The	_
28-2	5126-5128	RP	_
28-3	5129-5137	monetary	_
28-4	5138-5147	incentive	_
28-5	5148-5153	delay	_
28-6	5154-5158	task	_
28-7	5159-5166	allowed	_
28-8	5167-5170	the	_
28-9	5171-5176	study	_
28-10	5177-5179	of	_
28-11	5180-5192	anticipation	_
28-12	5193-5195	of	_
28-13	5196-5204	monetary	_
28-14	5205-5210	gains	_
28-15	5211-5213	or	_
28-16	5214-5220	losses	_
28-17	5221-5222	.	_

29-1	5223-5226	The	_
29-2	5227-5233	Theory	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
29-3	5234-5236	of	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
29-4	5237-5241	Mind	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
29-5	5242-5243	(	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
29-6	5244-5247	ToM	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
29-7	5248-5249	)	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
29-8	5250-5254	task	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
29-9	5255-5264	consisted	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
29-10	5265-5267	of	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
29-11	5268-5275	cartoon	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
29-12	5276-5283	stories	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
29-13	5284-5293	requiring	_
29-14	5294-5302	subjects	_
29-15	5303-5305	to	_
29-16	5306-5310	take	_
29-17	5311-5314	the	_
29-18	5315-5326	protagonist	_
29-19	5327-5328	’	_
29-20	5329-5330	s	_
29-21	5331-5342	perspective	_
29-22	5343-5346	and	_
29-23	5347-5352	judge	_
29-24	5353-5360	changes	_
29-25	5361-5363	in	_
29-26	5364-5371	his/her	_
29-27	5372-5381	affective	_
29-28	5382-5388	states	_
29-29	5389-5390	.	_

30-1	5391-5394	The	_
30-2	5395-5408	face-matching	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
30-3	5409-5413	task	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
30-4	5414-5415	(	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
30-5	5416-5419	FMT	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
30-6	5420-5421	)	http://maven.renci.org/NeuroBridge/neurobridge#FingerTappingTask
30-7	5422-5437	operationalized	_
30-8	5438-5446	subjects	_
30-9	5447-5448	’	_
30-10	5449-5457	implicit	_
30-11	5458-5468	processing	_
30-12	5469-5471	of	_
30-13	5472-5480	negative	_
30-14	5481-5489	emotions	_
30-15	5490-5495	while	_
30-16	5496-5503	viewing	_
30-17	5504-5509	faces	_
30-18	5510-5517	showing	_
30-19	5518-5524	either	_
30-20	5525-5532	fearful	_
30-21	5533-5535	or	_
30-22	5536-5541	angry	_
30-23	5542-5553	expressions	_
30-24	5554-5555	(	_
30-25	5556-5559	for	_
30-26	5560-5568	detailed	_
30-27	5569-5581	descriptions	_
30-28	5582-5585	see	_
30-29	5586-5590	refs	_
30-30	5591-5594	and	_
30-31	5595-5608	Supplementary	_
30-32	5609-5617	Material	_
30-33	5618-5619	)	_
30-34	5620-5621	.	_

31-1	5622-5625	All	_
31-2	5626-5631	tasks	_
31-3	5632-5636	were	_
31-4	5637-5647	previously	_
31-5	5648-5653	shown	_
31-6	5654-5656	to	_
31-7	5657-5665	robustly	_
31-8	5666-5674	activate	_
31-9	5675-5681	target	_
31-10	5682-5692	structures	_
31-11	5693-5696	and	_
31-12	5697-5699	to	_
31-13	5700-5707	possess	_
31-14	5708-5717	excellent	_
31-15	5718-5729	test–retest	_
31-16	5730-5741	reliability	_
31-17	5742-5744	in	_
31-18	5745-5758	between-group	_
31-19	5759-5766	designs	_
31-20	5767-5768	.	_

32-1	5769-5776	Imaging	_
32-2	5777-5787	parameters	_
32-3	5788-5806	Blood-oxygen-level	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
32-4	5807-5816	dependent	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
32-5	5817-5821	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
32-6	5822-5825	was	_
32-7	5826-5835	performed	_
32-8	5836-5838	on	_
32-9	5839-5844	three	_
32-10	5845-5852	Siemens	_
32-11	5853-5857	Trio	_
32-12	5858-5859	3	_
32-13	5860-5861	T	http://maven.renci.org/NeuroBridge/neurobridge#2Level
32-14	5862-5875	MR-Tomographs	http://maven.renci.org/NeuroBridge/neurobridge#2Level
32-15	5876-5878	at	_
32-16	5879-5882	the	_
32-17	5883-5887	Life	_
32-18	5888-5891	and	_
32-19	5892-5897	Brain	_
32-20	5898-5904	Center	_
32-21	5905-5907	of	_
32-22	5908-5911	the	_
32-23	5912-5922	University	_
32-24	5923-5925	of	_
32-25	5926-5930	Bonn	_
32-26	5931-5932	,	_
32-27	5933-5936	the	_
32-28	5937-5944	Central	_
32-29	5945-5954	Institute	_
32-30	5955-5957	of	_
32-31	5958-5964	Mental	_
32-32	5965-5971	Health	_
32-33	5972-5980	Mannheim	_
32-34	5981-5982	,	_
32-35	5983-5986	and	_
32-36	5987-5990	the	_
32-37	5991-6018	Charité-Universitätsmedizin	_
32-38	6019-6025	Berlin	_
32-39	6026-6027	.	_

33-1	6028-6030	At	_
33-2	6031-6034	all	_
33-3	6035-6040	sites	_
33-4	6041-6042	,	_
33-5	6043-6052	identical	_
33-6	6053-6062	sequences	_
33-7	6063-6066	and	_
33-8	6067-6074	scanner	_
33-9	6075-6084	protocols	_
33-10	6085-6089	were	_
33-11	6090-6098	employed	_
33-12	6099-6100	(	_
33-13	6101-6103	EM	_
33-14	6104-6105	:	_
33-15	6106-6108	33	_
33-16	6109-6115	slices	_
33-17	6116-6117	,	_
33-18	6118-6125	axially	_
33-19	6126-6132	tilted	_
33-20	6133-6134	(	_
33-21	6135-6139	−30°	_
33-22	6140-6141	)	_
33-23	6142-6143	,	_
33-24	6144-6149	slice	_
33-25	6150-6159	thickness	_
33-26	6160-6163	2.4	_
33-27	6164-6170	mm+0.6	_
33-28	6171-6173	mm	_
33-29	6174-6177	gap	_
33-30	6178-6179	,	_
33-31	6180-6185	field	_
33-32	6186-6188	of	_
33-33	6189-6193	view	_
33-34	6194-6195	(	_
33-35	6196-6199	FOV	_
33-36	6200-6201	)	_
33-37	6202-6205	192	_
33-38	6206-6208	mm	_
33-39	6209-6210	,	_
33-40	6211-6221	repetition	_
33-41	6222-6226	time	_
33-42	6227-6228	(	_
33-43	6229-6231	TR	_
33-44	6232-6233	)	_
33-45	6234-6238	1.96	_
33-46	6239-6240	s	_
33-47	6241-6242	,	_
33-48	6243-6247	echo	_
33-49	6248-6252	time	_
33-50	6253-6254	(	_
33-51	6255-6257	TE	_
33-52	6258-6259	)	_
33-53	6260-6262	30	_
33-54	6263-6265	ms	_
33-55	6266-6267	,	_
33-56	6268-6272	flip	_
33-57	6273-6278	angle	_
33-58	6279-6282	80°	_
33-59	6283-6284	,	_
33-60	6285-6288	all	_
33-61	6289-6294	other	_
33-62	6295-6299	fMRI	_
33-63	6300-6305	tasks	_
33-64	6306-6307	:	_
33-65	6308-6310	28	_
33-66	6311-6317	slices	_
33-67	6318-6319	,	_
33-68	6320-6325	slice	_
33-69	6326-6335	thickness	_
33-70	6336-6337	4	_
33-71	6338-6342	mm+1	_
33-72	6343-6345	mm	_
33-73	6346-6349	gap	_
33-74	6350-6351	,	_
33-75	6352-6355	FOV	_
33-76	6356-6359	192	_
33-77	6360-6362	mm	_
33-78	6363-6364	,	_
33-79	6365-6367	TR	_
33-80	6368-6369	2	_
33-81	6370-6371	s	_
33-82	6372-6373	,	_
33-83	6374-6376	TE	_
33-84	6377-6379	30	_
33-85	6380-6382	ms	_
33-86	6383-6384	,	_
33-87	6385-6389	flip	_
33-88	6390-6395	angle	_
33-89	6396-6399	80°	_
33-90	6400-6401	)	_
33-91	6402-6403	.	_

34-1	6404-6419	Quality-control	_
34-2	6420-6432	measurements	_
34-3	6433-6437	were	_
34-4	6438-6447	conducted	_
34-5	6448-6450	at	_
34-6	6451-6454	all	_
34-7	6455-6460	sites	_
34-8	6461-6463	on	_
34-9	6464-6469	every	_
34-10	6470-6473	day	_
34-11	6474-6476	of	_
34-12	6477-6481	data	_
34-13	6482-6492	collection	_
34-14	6493-6502	according	_
34-15	6503-6505	to	_
34-16	6506-6507	a	_
34-17	6508-6519	multicenter	_
34-18	6520-6537	quality-assurance	_
34-19	6538-6546	protocol	_
34-20	6547-6548	,	_
34-21	6549-6558	revealing	_
34-22	6559-6565	stable	_
34-23	6566-6576	parameters	_
34-24	6577-6581	over	_
34-25	6582-6586	time	_
34-26	6587-6588	.	_

35-1	6589-6591	To	_
35-2	6592-6599	account	_
35-3	6600-6603	for	_
35-4	6604-6607	any	_
35-5	6608-6616	variance	_
35-6	6617-6624	related	_
35-7	6625-6627	to	_
35-8	6628-6639	differences	_
35-9	6640-6646	across	_
35-10	6647-6652	sites	_
35-11	6653-6654	,	_
35-12	6655-6658	the	_
35-13	6659-6663	site	_
35-14	6664-6667	was	_
35-15	6668-6672	used	_
35-16	6673-6675	as	_
35-17	6676-6677	a	_
35-18	6678-6687	covariate	_
35-19	6688-6691	for	_
35-20	6692-6695	all	_
35-21	6696-6707	statistical	_
35-22	6708-6716	analyses	_
35-23	6717-6718	.	_

36-1	6719-6729	Functional	_
36-2	6730-6735	image	_
36-3	6736-6746	processing	_
36-4	6747-6752	Image	_
36-5	6753-6763	processing	_
36-6	6764-6767	and	_
36-7	6768-6779	statistical	_
36-8	6780-6788	analyses	_
36-9	6789-6793	were	_
36-10	6794-6803	conducted	_
36-11	6804-6809	using	_
36-12	6810-6821	statistical	_
36-13	6822-6832	parametric	_
36-14	6833-6840	mapping	_
36-15	6841-6848	methods	_
36-16	6849-6851	as	_
36-17	6852-6863	implemented	_
36-18	6864-6866	in	_
36-19	6867-6871	SPM8	_
36-20	6872-6873	(	_
36-21	6874-6878	http	_
36-22	6879-6880	:	_
36-23	6881-6923	//www.fil.ion.ucl.ac.uk/spm/software/spm8/	_
36-24	6924-6925	)	_
36-25	6926-6927	.	_

37-1	6928-6933	Scans	_
37-2	6934-6938	were	_
37-3	6939-6948	subjected	_
37-4	6949-6951	to	_
37-5	6952-6953	a	_
37-6	6954-6960	strict	_
37-7	6961-6968	quality	_
37-8	6969-6979	assessment	_
37-9	6980-6986	before	_
37-10	6987-6996	inclusion	_
37-11	6997-7001	into	_
37-12	7002-7009	further	_
37-13	7010-7018	analyses	_
37-14	7019-7020	.	_

38-1	7021-7030	Following	_
38-2	7031-7043	data-quality	_
38-3	7044-7054	assessment	_
38-4	7055-7058	and	_
38-5	7059-7070	application	_
38-6	7071-7073	of	_
38-7	7074-7081	general	_
38-8	7082-7091	exclusion	_
38-9	7092-7100	criteria	_
38-10	7101-7102	(	_
38-11	7103-7106	see	_
38-12	7107-7112	above	_
38-13	7113-7114	)	_
38-14	7115-7124	n=472–509	_
38-15	7125-7133	subjects	_
38-16	7134-7138	were	_
38-17	7139-7147	included	_
38-18	7148-7150	in	_
38-19	7151-7154	the	_
38-20	7155-7165	respective	_
38-21	7166-7174	analyses	_
38-22	7175-7176	(	_
38-23	7177-7180	see	_
38-24	7181-7194	Supplementary	_
38-25	7195-7201	Figure	_
38-26	7202-7203	1	_
38-27	7204-7207	and	_
38-28	7208-7221	Supplementary	_
38-29	7222-7229	Methods	_
38-30	7230-7233	for	_
38-31	7234-7241	details	_
38-32	7242-7243	)	_
38-33	7244-7245	.	_

39-1	7246-7252	During	_
39-2	7253-7267	pre-processing	_
39-3	7268-7269	,	_
39-4	7270-7276	images	_
39-5	7277-7281	were	_
39-6	7282-7291	realigned	_
39-7	7292-7294	to	_
39-8	7295-7296	a	_
39-9	7297-7301	mean	_
39-10	7302-7307	image	_
39-11	7308-7309	(	_
39-12	7310-7318	movement	_
39-13	7319-7329	parameters	_
39-14	7330-7338	confined	_
39-15	7339-7341	to	_
39-16	7342-7343	<	_
39-17	7344-7345	3	_
39-18	7346-7348	mm	_
39-19	7349-7360	translation	_
39-20	7361-7364	and	_
39-21	7365-7366	<	_
39-22	7367-7371	1.7°	_
39-23	7372-7380	rotation	_
39-24	7381-7388	between	_
39-25	7389-7396	volumes	_
39-26	7397-7398	)	_
39-27	7399-7400	,	_
39-28	7401-7421	slice-time-corrected	_
39-29	7422-7423	,	_
39-30	7424-7433	spatially	_
39-31	7434-7444	normalized	_
39-32	7445-7447	to	_
39-33	7448-7449	a	_
39-34	7450-7458	standard	_
39-35	7459-7471	stereotactic	_
39-36	7472-7477	space	_
39-37	7478-7479	(	_
39-38	7480-7481	a	_
39-39	7482-7487	brain	_
39-40	7488-7496	template	_
39-41	7497-7504	created	_
39-42	7505-7507	by	_
39-43	7508-7511	the	_
39-44	7512-7520	Montreal	_
39-45	7521-7533	Neurological	_
39-46	7534-7543	Institute	_
39-47	7544-7545	)	_
39-48	7546-7550	with	_
39-49	7551-7552	a	_
39-50	7553-7558	voxel	_
39-51	7559-7563	size	_
39-52	7564-7566	of	_
39-53	7567-7568	3	_
39-54	7569-7570	×	_
39-55	7571-7572	3	_
39-56	7573-7574	×	_
39-57	7575-7576	3	_
39-58	7577-7579	mm	_
39-59	7580-7583	and	_
39-60	7584-7592	smoothed	_
39-61	7593-7597	with	_
39-62	7598-7599	a	_
39-63	7600-7601	9	_
39-64	7602-7604	mm	_
39-65	7605-7609	full	_
39-66	7610-7615	width	_
39-67	7616-7618	at	_
39-68	7619-7623	half	_
39-69	7624-7631	maximum	_
39-70	7632-7640	Gaussian	_
39-71	7641-7647	filter	_
39-72	7648-7649	.	_

40-1	7650-7651	A	_
40-2	7652-7663	first-level	_
40-3	7664-7677	fixed-effects	_
40-4	7678-7683	model	_
40-5	7684-7687	was	_
40-6	7688-7696	computed	_
40-7	7697-7700	for	_
40-8	7701-7705	each	_
40-9	7706-7717	participant	_
40-10	7718-7721	and	_
40-11	7722-7726	task	_
40-12	7727-7728	.	_

41-1	7729-7739	Regressors	_
41-2	7740-7744	were	_
41-3	7745-7752	created	_
41-4	7753-7757	from	_
41-5	7758-7761	the	_
41-6	7762-7766	time	_
41-7	7767-7773	course	_
41-8	7774-7776	of	_
41-9	7777-7780	the	_
41-10	7781-7793	experimental	_
41-11	7794-7804	conditions	_
41-12	7805-7807	of	_
41-13	7808-7816	interest	_
41-14	7817-7820	per	_
41-15	7821-7825	task	_
41-16	7826-7829	and	_
41-17	7830-7839	convolved	_
41-18	7840-7844	with	_
41-19	7845-7846	a	_
41-20	7847-7856	canonical	_
41-21	7857-7868	hemodynamic	_
41-22	7869-7877	response	_
41-23	7878-7886	function	_
41-24	7887-7888	.	_

42-1	7889-7897	Movement	_
42-2	7898-7908	parameters	_
42-3	7909-7910	,	_
42-4	7911-7914	and	_
42-5	7915-7918	for	_
42-6	7919-7922	the	_
42-7	7923-7926	ToM	_
42-8	7927-7931	task	_
42-9	7932-7936	also	_
42-10	7937-7949	instructions	_
42-11	7950-7953	and	_
42-12	7954-7960	button	_
42-13	7961-7968	presses	_
42-14	7969-7970	,	_
42-15	7971-7975	were	_
42-16	7976-7984	included	_
42-17	7985-7987	in	_
42-18	7988-7991	the	_
42-19	7992-8003	first-level	_
42-20	8004-8010	models	_
42-21	8011-8013	as	_
42-22	8014-8024	covariates	_
42-23	8025-8027	of	_
42-24	8028-8030	no	_
42-25	8031-8039	interest	_
42-26	8040-8041	.	_

43-1	8042-8045	For	_
43-2	8046-8050	each	_
43-3	8051-8058	subject	_
43-4	8059-8060	,	_
43-5	8061-8071	individual	_
43-6	8072-8080	contrast	_
43-7	8081-8087	images	_
43-8	8088-8090	of	_
43-9	8091-8094	the	_
43-10	8095-8099	task	_
43-11	8100-8106	effect	_
43-12	8107-8108	(	_
43-13	8109-8111	WM	_
43-14	8112-8113	:	_
43-15	8114-8120	2-back	_
43-16	8121-8122	>	_
43-17	8123-8129	0-back	_
43-18	8130-8131	;	_
43-19	8132-8134	EM	_
43-20	8135-8136	:	_
43-21	8137-8143	memory	_
43-22	8144-8145	>	_
43-23	8146-8153	control	_
43-24	8154-8155	;	_
43-25	8156-8158	RP	_
43-26	8159-8160	:	_
43-27	8161-8173	anticipation	_
43-28	8174-8176	of	_
43-29	8177-8185	monetary	_
43-30	8186-8194	win/loss	_
43-31	8195-8196	>	_
43-32	8197-8209	anticipation	_
43-33	8210-8212	of	_
43-34	8213-8220	neutral	_
43-35	8221-8229	outcomes	_
43-36	8230-8231	;	_
43-37	8232-8235	ToM	_
43-38	8236-8237	:	_
43-39	8238-8249	mentalizing	_
43-40	8250-8251	>	_
43-41	8252-8259	control	_
43-42	8260-8261	;	_
43-43	8262-8265	FMT	_
43-44	8266-8267	:	_
43-45	8268-8273	faces	_
43-46	8274-8275	>	_
43-47	8276-8282	shapes	_
43-48	8283-8284	)	_
43-49	8285-8289	were	_
43-50	8290-8302	subsequently	_
43-51	8303-8310	entered	_
43-52	8311-8315	into	_
43-53	8316-8321	group	_
43-54	8322-8332	statistics	_
43-55	8333-8334	.	_

44-1	8335-8346	Statistical	_
44-2	8347-8352	group	_
44-3	8353-8361	analyses	_
44-4	8362-8365	RPS	_
44-5	8366-8367	:	_
44-6	8368-8370	To	_
44-7	8371-8375	test	_
44-8	8376-8379	for	_
44-9	8380-8387	genetic	_
44-10	8388-8399	association	_
44-11	8400-8404	with	_
44-12	8405-8408	the	_
44-13	8409-8421	intermediate	_
44-14	8422-8432	phenotypes	_
44-15	8433-8434	,	_
44-16	8435-8438	the	_
44-17	8439-8449	respective	_
44-18	8450-8460	individual	_
44-19	8461-8469	contrast	_
44-20	8470-8476	images	_
44-21	8477-8481	were	_
44-22	8482-8490	analyzed	_
44-23	8491-8496	using	_
44-24	8497-8509	second-level	_
44-25	8510-8518	multiple	_
44-26	8519-8529	regression	_
44-27	8530-8536	models	_
44-28	8537-8540	for	_
44-29	8541-8545	each	_
44-30	8546-8550	task	_
44-31	8551-8552	,	_
44-32	8553-8562	including	_
44-33	8563-8566	the	_
44-34	8567-8570	RPS	_
44-35	8571-8573	as	_
44-36	8574-8583	regressor	_
44-37	8584-8586	of	_
44-38	8587-8595	interest	_
44-39	8596-8597	,	_
44-40	8598-8601	and	_
44-41	8602-8605	age	_
44-42	8606-8607	,	_
44-43	8608-8611	sex	_
44-44	8612-8613	,	_
44-45	8614-8618	site	_
44-46	8619-8620	,	_
44-47	8621-8629	subgroup	_
44-48	8630-8631	(	_
44-49	8632-8634	no	_
44-50	8635-8643	familial	_
44-51	8644-8653	liability	_
44-52	8654-8657	for	_
44-53	8658-8669	psychiatric	_
44-54	8670-8679	disorders	_
44-55	8680-8681	,	_
44-56	8682-8690	affected	_
44-57	8691-8703	first-degree	_
44-58	8704-8712	relative	_
44-59	8713-8715	of	_
44-60	8716-8724	patients	_
44-61	8725-8729	with	_
44-62	8730-8743	schizophrenia	_
44-63	8744-8745	,	_
44-64	8746-8753	bipolar	_
44-65	8754-8762	disorder	_
44-66	8763-8765	or	_
44-67	8766-8776	depression	_
44-68	8777-8778	)	_
44-69	8779-8780	,	_
44-70	8781-8785	chip	_
44-71	8786-8790	used	_
44-72	8791-8794	for	_
44-73	8795-8805	genotyping	_
44-74	8806-8809	and	_
44-75	8810-8813	the	_
44-76	8814-8819	first	_
44-77	8820-8825	three	_
44-78	8826-8835	principal	_
44-79	8836-8846	components	_
44-80	8847-8848	(	_
44-81	8849-8856	derived	_
44-82	8857-8861	from	_
44-83	8862-8863	a	_
44-84	8864-8877	statistically	_
44-85	8878-8889	independent	_
44-86	8890-8893	set	_
44-87	8894-8896	of	_
44-88	8897-8903	common	_
44-89	8904-8908	SNPs	_
44-90	8909-8921	representing	_
44-91	8922-8931	potential	_
44-92	8932-8942	population	_
44-93	8943-8957	stratification	_
44-94	8958-8959	)	_
44-95	8960-8962	as	_
44-96	8963-8971	nuisance	_
44-97	8972-8982	covariates	_
44-98	8983-8984	.	_

45-1	8985-8992	Effects	_
45-2	8993-8995	of	_
45-3	8996-8999	RPS	_
45-4	9000-9002	on	_
45-5	9003-9013	predefined	_
45-6	9014-9021	regions	_
45-7	9022-9024	of	_
45-8	9025-9033	interest	_
45-9	9034-9035	(	_
45-10	9036-9040	ROIs	_
45-11	9041-9042	)	_
45-12	9043-9047	were	_
45-13	9048-9056	assessed	_
45-14	9057-9068	determining	_
45-15	9069-9072	the	_
45-16	9073-9083	familywise	_
45-17	9084-9089	error	_
45-18	9090-9091	(	_
45-19	9092-9095	FWE	_
45-20	9096-9097	)	_
45-21	9098-9108	-corrected	_
45-22	9109-9121	significance	_
45-23	9122-9128	values	_
45-24	9129-9131	of	_
45-25	9132-9135	the	_
45-26	9136-9145	maximally	_
45-27	9146-9155	activated	_
45-28	9156-9161	voxel	_
45-29	9162-9168	within	_
45-30	9169-9173	each	_
45-31	9174-9177	ROI	_
45-32	9178-9183	using	_
45-33	9184-9194	undirected	_
45-34	9195-9200	tests	_
45-35	9201-9202	.	_

46-1	9203-9206	For	_
46-2	9207-9210	the	_
46-3	9211-9213	WM	_
46-4	9214-9215	,	_
46-5	9216-9218	EM	_
46-6	9219-9222	and	_
46-7	9223-9226	FMT	_
46-8	9227-9232	tasks	_
46-9	9233-9234	,	_
46-10	9235-9239	ROIs	_
46-11	9240-9244	were	_
46-12	9245-9252	defined	_
46-13	9253-9254	a	_
46-14	9255-9261	priori	_
46-15	9262-9267	using	_
46-16	9268-9278	anatomical	_
46-17	9279-9285	labels	_
46-18	9286-9294	provided	_
46-19	9295-9297	by	_
46-20	9298-9301	the	_
46-21	9302-9306	Wake	_
46-22	9307-9313	Forest	_
46-23	9314-9324	University	_
46-24	9325-9329	Pick	_
46-25	9330-9335	Atlas	_
46-26	9336-9337	(	_
46-27	9338-9367	www.fmri.wfubmc.edu/downloads	_
46-28	9368-9369	)	_
46-29	9370-9371	.	_

47-1	9372-9377	These	_
47-2	9378-9382	were	_
47-3	9383-9386	the	_
47-4	9387-9396	bilateral	_
47-5	9397-9409	dorsolateral	_
47-6	9410-9420	prefrontal	_
47-7	9421-9427	cortex	_
47-8	9428-9429	(	_
47-9	9430-9434	BA46	_
47-10	9435-9438	and	_
47-11	9439-9442	BA9	_
47-12	9443-9447	with	_
47-13	9448-9459	subtraction	_
47-14	9460-9462	of	_
47-15	9463-9469	medial	_
47-16	9470-9476	voxels	_
47-17	9477-9479	of	_
47-18	9480-9483	BA9	_
47-19	9484-9485	,	_
47-20	9486-9489	see	_
47-21	9490-9499	Esslinger	_
47-22	9500-9502	et	_
47-23	9503-9505	al	_
47-24	9506-9507	.	_

48-1	9508-9511	for	_
48-2	9512-9519	details	_
48-3	9520-9521	)	_
48-4	9522-9525	for	_
48-5	9526-9529	the	_
48-6	9530-9532	WM	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
48-7	9533-9537	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
48-8	9538-9539	,	_
48-9	9540-9543	the	_
48-10	9544-9548	left	_
48-11	9549-9552	and	_
48-12	9553-9558	right	_
48-13	9559-9570	hippocampus	_
48-14	9571-9574	and	_
48-15	9575-9585	perigenual	_
48-16	9586-9594	anterior	_
48-17	9595-9604	cingulate	_
48-18	9605-9611	cortex	_
48-19	9612-9613	(	_
48-20	9614-9619	pgACC	_
48-21	9620-9621	)	_
48-22	9622-9625	for	_
48-23	9626-9628	EM	http://maven.renci.org/NeuroBridge/neurobridge#Thing
48-24	9629-9634	tasks	_
48-25	9635-9638	and	_
48-26	9639-9642	the	_
48-27	9643-9652	bilateral	_
48-28	9653-9661	amygdala	_
48-29	9662-9663	,	_
48-30	9664-9666	as	_
48-31	9667-9671	well	_
48-32	9672-9674	as	_
48-33	9675-9678	the	_
48-34	9679-9684	pgACC	_
48-35	9685-9688	for	_
48-36	9689-9692	the	_
48-37	9693-9696	FMT	_
48-38	9697-9698	(	_
48-39	9699-9712	Supplementary	_
48-40	9713-9719	Figure	_
48-41	9720-9722	S2	_
48-42	9723-9724	)	_
48-43	9725-9726	.	_

49-1	9727-9729	As	_
49-2	9730-9733	the	_
49-3	9734-9737	AAL	_
49-4	9738-9743	atlas	_
49-5	9744-9748	does	_
49-6	9749-9752	not	_
49-7	9753-9760	provide	_
49-8	9761-9771	anatomical	_
49-9	9772-9778	labels	_
49-10	9779-9782	for	_
49-11	9783-9786	the	_
49-12	9787-9794	ventral	_
49-13	9795-9803	striatum	_
49-14	9804-9805	,	_
49-15	9806-9807	a	_
49-16	9808-9817	spherical	_
49-17	9818-9821	ROI	_
49-18	9822-9825	was	_
49-19	9826-9833	created	_
49-20	9834-9837	for	_
49-21	9838-9841	the	_
49-22	9842-9844	RP	_
49-23	9845-9849	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
49-24	9850-9855	using	_
49-25	9856-9857	a	_
49-26	9858-9863	voxel	_
49-27	9864-9871	located	_
49-28	9872-9874	in	_
49-29	9875-9878	the	_
49-30	9879-9885	center	_
49-31	9886-9888	of	_
49-32	9889-9892	the	_
49-33	9893-9900	ventral	_
49-34	9901-9909	striatum	_
49-35	9910-9911	(	_
49-36	9912-9916	x=±9	_
49-37	9917-9918	,	_
49-38	9919-9923	y=11	_
49-39	9924-9925	,	_
49-40	9926-9930	z=−8	_
49-41	9931-9932	)	_
49-42	9933-9943	surrounded	_
49-43	9944-9946	by	_
49-44	9947-9948	a	_
49-45	9949-9955	sphere	_
49-46	9956-9958	of	_
49-47	9959-9961	10	_
49-48	9962-9964	mm	_
49-49	9965-9966	.	_

50-1	9967-9970	For	_
50-2	9971-9974	the	_
50-3	9975-9978	ToM	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
50-4	9979-9983	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
50-5	9984-9985	,	_
50-6	9986-9990	four	_
50-7	9991-10001	functional	_
50-8	10002-10006	ROIs	_
50-9	10007-10011	were	_
50-10	10012-10019	created	_
50-11	10020-10023	for	_
50-12	10024-10029	those	_
50-13	10030-10037	regions	_
50-14	10038-10048	previously	_
50-15	10049-10054	shown	_
50-16	10055-10057	to	_
50-17	10058-10060	be	_
50-18	10061-10071	aberrantly	_
50-19	10072-10081	activated	_
50-20	10082-10084	in	_
50-21	10085-10093	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
50-22	10094-10098	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
50-23	10099-10112	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
50-24	10113-10114	(	_
50-25	10115-10118	for	_
50-26	10119-10126	example	_
50-27	10127-10128	,	_
50-28	10129-10138	Sugranyes	_
50-29	10139-10141	et	_
50-30	10142-10144	al	_
50-31	10145-10146	.	_

51-1	10147-10148	;	_
51-2	10149-10155	Walter	_
51-3	10156-10158	et	_
51-4	10159-10161	al	_
51-5	10162-10163	.	_
51-6	10164-10165	)	_

52-1	10166-10169	and	_
52-2	10170-10172	to	_
52-3	10173-10175	be	_
52-4	10176-10187	genetically	_
52-5	10188-10197	modulated	_
52-6	10198-10199	.	_

53-1	10200-10202	As	_
53-2	10203-10208	these	_
53-3	10209-10216	regions	_
53-4	10217-10221	were	_
53-5	10222-10225	not	_
53-6	10226-10233	covered	_
53-7	10234-10236	by	_
53-8	10237-10245	specific	_
53-9	10246-10249	AAL	_
53-10	10250-10254	ROIs	_
53-11	10255-10256	,	_
53-12	10257-10262	masks	_
53-13	10263-10266	for	_
53-14	10267-10270	the	_
53-15	10271-10277	medial	_
53-16	10278-10288	prefrontal	_
53-17	10289-10295	cortex	_
53-18	10296-10297	,	_
53-19	10298-10307	bilateral	_
53-20	10308-10316	temporal	_
53-21	10317-10325	parietal	_
53-22	10326-10334	junction	_
53-23	10335-10336	(	_
53-24	10337-10340	TPJ	_
53-25	10341-10342	)	_
53-26	10343-10346	and	_
53-27	10347-10356	posterior	_
53-28	10357-10366	cingulate	_
53-29	10367-10383	cortex/precuneus	_
53-30	10384-10385	(	_
53-31	10386-10393	PCC/Pcu	_
53-32	10394-10395	)	_
53-33	10396-10400	were	_
53-34	10401-10408	created	_
53-35	10409-10414	based	_
53-36	10415-10417	on	_
53-37	10418-10429	coordinates	_
53-38	10430-10438	reported	_
53-39	10439-10441	by	_
53-40	10442-10443	a	_
53-41	10444-10457	meta-analysis	_
53-42	10458-10460	on	_
53-43	10461-10466	brain	_
53-44	10467-10472	areas	_
53-45	10473-10481	involved	_
53-46	10482-10484	in	_
53-47	10485-10488	ToM	_
53-48	10489-10494	using	_
53-49	10495-10498	the	_
53-50	10499-10506	toolbox	_
53-51	10507-10513	TWURoi	_
53-52	10514-10515	(	_
53-53	10516-10519	see	_
53-54	10520-10533	Supplementary	_
53-55	10534-10542	Material	_
53-56	10543-10546	for	_
53-57	10547-10554	details	_
53-58	10555-10556	)	_
53-59	10557-10558	.	_

54-1	10559-10565	Single	_
54-2	10566-10569	SNP	_
54-3	10570-10574	fMRI	_
54-4	10575-10583	analyses	_
54-5	10584-10594	Comparable	_
54-6	10595-10597	to	_
54-7	10598-10601	RPS	_
54-8	10602-10610	analyses	_
54-9	10611-10612	,	_
54-10	10613-10625	second-level	_
54-11	10626-10634	multiple	_
54-12	10635-10645	regression	_
54-13	10646-10652	models	_
54-14	10653-10657	were	_
54-15	10658-10666	computed	_
54-16	10667-10670	for	_
54-17	10671-10675	each	_
54-18	10676-10679	SNP	_
54-19	10680-10683	and	_
54-20	10684-10688	each	_
54-21	10689-10693	task	_
54-22	10694-10698	with	_
54-23	10699-10705	number	_
54-24	10706-10708	of	_
54-25	10709-10714	minor	_
54-26	10715-10722	alleles	_
54-27	10723-10725	as	_
54-28	10726-10735	regressor	_
54-29	10736-10738	of	_
54-30	10739-10747	interest	_
54-31	10748-10749	,	_
54-32	10750-10753	and	_
54-33	10754-10757	age	_
54-34	10758-10759	,	_
54-35	10760-10763	sex	_
54-36	10764-10765	,	_
54-37	10766-10770	site	_
54-38	10771-10772	,	_
54-39	10773-10781	subgroup	_
54-40	10782-10783	,	_
54-41	10784-10794	genotyping	_
54-42	10795-10799	chip	_
54-43	10800-10803	and	_
54-44	10804-10807	the	_
54-45	10808-10813	first	_
54-46	10814-10819	three	_
54-47	10820-10829	principal	_
54-48	10830-10840	components	_
54-49	10841-10843	of	_
54-50	10844-10853	potential	_
54-51	10854-10864	population	_
54-52	10865-10879	stratification	_
54-53	10880-10882	as	_
54-54	10883-10891	nuisance	_
54-55	10892-10902	covariates	_
54-56	10903-10904	.	_

55-1	10905-10907	We	_
55-2	10908-10916	excluded	_
55-3	10917-10921	SNPs	_
55-4	10922-10926	with	_
55-5	10927-10931	less	_
55-6	10932-10936	than	_
55-7	10937-10939	10	_
55-8	10940-10948	subjects	_
55-9	10949-10951	in	_
55-10	10952-10955	one	_
55-11	10956-10963	allelic	_
55-12	10964-10969	group	_
55-13	10970-10971	,	_
55-14	10972-10981	resulting	_
55-15	10982-10984	in	_
55-16	10985-10988	105	_
55-17	10989-11000	independent	_
55-18	11001-11009	analyses	_
55-19	11010-11011	.	_

56-1	11012-11019	Similar	_
56-2	11020-11022	to	_
56-3	11023-11026	RPS	_
56-4	11027-11035	analyses	_
56-5	11036-11037	,	_
56-6	11038-11040	we	_
56-7	11041-11050	extracted	_
56-8	11051-11064	FWE-corrected	_
56-9	11065-11073	P-values	_
56-10	11074-11076	of	_
56-11	11077-11080	the	_
56-12	11081-11090	maximally	_
56-13	11091-11100	activated	_
56-14	11101-11106	voxel	_
56-15	11107-11113	within	_
56-16	11114-11118	each	_
56-17	11119-11122	ROI	_
56-18	11123-11126	for	_
56-19	11127-11131	each	_
56-20	11132-11135	SNP	_
56-21	11136-11140	from	_
56-22	11141-11143	an	_
56-23	11144-11154	undirected	_
56-24	11155-11159	test	_
56-25	11160-11161	.	_

57-1	11162-11167	These	_
57-2	11168-11180	significance	_
57-3	11181-11187	values	_
57-4	11188-11192	were	_
57-5	11193-11197	then	_
57-6	11198-11218	Bonferroni-corrected	_
57-7	11219-11222	for	_
57-8	11223-11226	the	_
57-9	11227-11233	number	_
57-10	11234-11236	of	_
57-11	11237-11246	autosomal	_
57-12	11247-11251	SNPs	_
57-13	11252-11258	tested	_
57-14	11259-11260	,	_
57-15	11261-11265	that	_
57-16	11266-11268	is	_
57-17	11269-11270	,	_
57-18	11271-11274	105	_
57-19	11275-11276	(	_
57-20	11277-11278	P	_
57-21	11279-11280	<	_
57-22	11281-11285	4.76	_
57-23	11286-11287	×	_
57-24	11288-11292	10−4	_
57-25	11293-11294	)	_
57-26	11295-11296	.	_

58-1	11297-11299	We	_
58-2	11300-11304	used	_
58-3	11305-11307	an	_
58-4	11308-11318	undirected	_
58-5	11319-11325	F-test	_
58-6	11326-11328	in	_
58-7	11329-11332	all	_
58-8	11333-11341	analyses	_
58-9	11342-11343	,	_
58-10	11344-11346	as	_
58-11	11347-11348	,	_
58-12	11349-11352	for	_
58-13	11353-11356	the	_
58-14	11357-11369	investigated	_
58-15	11370-11373	RPS	_
58-16	11374-11377	and	_
58-17	11378-11381	the	_
58-18	11382-11386	vast	_
58-19	11387-11395	majority	_
58-20	11396-11398	of	_
58-21	11399-11403	SNPs	_
58-22	11404-11405	,	_
58-23	11406-11408	we	_
58-24	11409-11412	had	_
58-25	11413-11415	no	_
58-26	11416-11426	hypotheses	_
58-27	11427-11432	about	_
58-28	11433-11436	the	_
58-29	11437-11451	directionality	_
58-30	11452-11454	of	_
58-31	11455-11462	effects	_
58-32	11463-11464	.	_

59-1	11465-11477	Associations	_
59-2	11478-11482	with	_
59-3	11483-11486	the	_
59-4	11487-11499	intermediate	_
59-5	11500-11509	phenotype	_
59-6	11510-11515	could	_
59-7	11516-11518	be	_
59-8	11519-11530	represented	_
59-9	11531-11533	by	_
59-10	11534-11541	reduced	_
59-11	11542-11544	or	_
59-12	11545-11554	increased	_
59-13	11555-11565	activation	_
59-14	11566-11567	,	_
59-15	11568-11573	being	_
59-16	11574-11580	either	_
59-17	11581-11591	indicative	_
59-18	11592-11594	of	_
59-19	11595-11606	dysfunction	_
59-20	11607-11608	,	_
59-21	11609-11621	inefficiency	_
59-22	11622-11624	or	_
59-23	11625-11637	compensatory	_
59-24	11638-11648	resilience	_
59-25	11649-11659	mechanisms	_
59-26	11660-11661	.	_

